MORRISVILLE, N.C.--(BUSINESS WIRE)--Arrivo Bio will be giving both an oral and poster presentation at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, taking place May 26–29 in Miami, Florida. The presentations will highlight Forvisirvat (SP-624), Arrivo’s first-in-class oral activator of the SIRT6 enzyme, currently in a Phase 2b/3 study for major depressive disorder, with data read out expected later this year. Prior Phase 2 data demonstrated a signal of efficacy

ALAMEDA, Calif.--(BUSINESS WIRE)--Scribe Therapeutics, Inc. (Scribe), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, today announced that it has secured clearance from the Australian Therapeutic Goods Administration (TGA) to initiate a first-in-human clinical study of STX-1150 for the treatment of hypercholesterolemia, a major driver of atheroscleroti

Media Release COPENHAGEN, Denmark; May 21, 2026 Twenty-three abstracts will highlight the versatility and strength of Genmab’s portfolio and pipeline, including data from the comprehensive epcoritamab development program, including 4 oral presentations Three abstracts will show the ongoing clinical trial evaluations of the safety and efficacy of Genmab’s investigational late-stage medicines, rinatabart sesutecan and petosemtamab Data evaluating epcoritamab will demonstrate outcomes across monot

NEW YORK, NY May 21, 2026 — ACA Pharma and Azurity Pharmaceuticals announced that Feraheme® and Ferabright™ have each received regulatory approval in Macau, marking an important step in expanding access to ferumoxytol-based products across key markets in Asia. These approvals reflect the continued collaboration between ACA Pharma and Azurity to advance regulatory pathways and improve patient access throughout Greater China. Macau remains an important entry point for innovative th

Transaction Adds Clinical and Preclinical CAR-T Programs Targeting Hematologic Malignancies and Solid TumorsFULLERTON, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (“Liminatus” or the “Company”) today announced that it has entered into a definitive Merger Agreement dated May 17, 2026, with InnocsAI LLC (“InnocsAI”), a biotechnology company focused on advanced CAR-T and antibody-based oncology therapies. Under the terms of the Merger Agreement, InnocsAI will merge with and i

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform in Canada. This is Hims & Hers’ first international generic GLP-1 offering, demonstrating the company’s ability to meet the unique needs of each global market it serves while continuing its international expansion efforts. Personalized treatment plans are available starting at $149 CAD/month, making effective

Eli Lilly's retatrutide was associated with average weight loss of up to 28.3% over 80 weeks in adults with obesity or overweight, marking the second pivotal study success for the 'triple-G' drug this year. Dan Skovronsky, the company's chief scientific and product officer, said "we haven’t seen that level of weight loss before with these kinds of medicines."Having reported a similar level of weight reduction in patients with knee osteoarthritis in December, as well as success in a diabetes stud

Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumors SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois from May 29 to June 2, 2026. Poster Presentation Title: Cohort Expansion of a Phase I Study of PLN-101095, a First-in-Class

Data from Phase 1b dose escalation and expansion trial (n=69) shows a favorable safety profile, with manageable adverse events consistent with the known profiles of the respective drugs. Encouraging preliminary signals of efficacy for the higher dose combination cohorts of HC-7366 with belzutifan were observed. Additionally, several patients in the dose escalation and initial expansion (Expansion 1) remain on treatment. Translational analyses demonstrate clear evidence of HC-7366 pathway engage

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a significant expansion of its operations, marking a major milestone in the company’s continued growth and mission to improve outcomes for patients with cancer and other serious diseases. At its North Austin headquarters campus, Natera will unveil two major expansion projects: a dedicated sequencing facility, significantly increasing capacity; and an additional sp